Cargando…

Efficacy and Safety of Leuprolide Acetate 6-Month Depot for the Treatment of Central Precocious Puberty: A Phase 3 Study

CONTEXT: Treatment options for central precocious puberty (CPP) are important for individualization of therapy. OBJECTIVE: We evaluated the efficacy and safety of 6-month 45-mg leuprolide acetate (LA) depot with intramuscular administration. METHODS: LA depot was administered at weeks 0 and 24 to tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klein, Karen O, Mauras, Nelly, Nayak, Sunil, Sunil, Bhuvana, Martinez-Placencia, Blanca M, Dragnic, Sanja, Ballina, Mayra, Zhou, Qing, Kansra, Alvina R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Clinical Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274571/ https://www.ncbi.nlm.nih.gov/pubmed/37334213 http://dx.doi.org/10.1210/jendso/bvad071

Ejemplares similares

Leuprolide Acetate 1-Month Depot for Central Precocious Puberty: Hormonal Suppression and Recovery
por: Neely, E. Kirk, et al.
Publicado: (2010)

Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty
por: Klein, Karen O, et al.
Publicado: (2020)

Pseudotumor cerebri in patient on leuprolide acetate for central precocious puberty
por: Omar, Anjumanara Anver, et al.
Publicado: (2020)

Multicenter clinical trial of leuprolide acetate depot (Luphere depot 3.75 mg) for efficacy and safety in girls with central precocious puberty
por: Kim, You Jin, et al.
Publicado: (2013)

Treatment with Depot Leuprolide Acetate in Girls with Idiopathic Precocious Puberty: What Parameter should be Used in Deciding on the Initial Dose?
por: Vurallı, Doğuş, et al.
Publicado: (2020)

Efficacy of Leuprolide Acetate 1-Month Depot for Central Precocious Puberty (CPP): Growth Outcomes During a Prospective, Longitudinal Study
por: Lee, Peter A, et al.
Publicado: (2011)

6-Month Subcutaneous Leuprolide Acetate Effectively Suppresses Clinical Signs of Puberty in Children With Central Precocious Puberty
por: Eugster, Erica A, et al.
Publicado: (2021)

Clinical development of the GnRH agonist leuprolide acetate depot
por: Chwalisz, Kristof
Publicado: (2022)

ODP397 Small-volume, Subcutaneous, 6-month Leuprolide Acetate Effectively Reduces Growth Velocity to Prepubertal Levels in Children with Central Precocious Puberty
por: Klein, Karen O, et al.
Publicado: (2022)

Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies
por: Spitz, Aaron, et al.
Publicado: (2016)

Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer
por: Spitz, A, et al.
Publicado: (2012)

THU195 6-Month Subcutaneous Leuprolide Acetate Achieved And Maintained Hormonal And Clinical Suppression In All Weight Groups Of Children With Central Precocious Puberty
por: Miller, Bradley S, et al.
Publicado: (2023)

Leuprolide and triptorelin treatment in children with idiopathic central precocious puberty: an efficacy/tolerability comparison study
por: Valenzise, M., et al.
Publicado: (2023)

Elevated Random Luteinizing Hormone is an Unreliable Indicator for Pubertal Suppression in Girls Treated with Monthly Leuprolide for Idiopathic Central Precocious Puberty
por: Wiromrat, Pattara, et al.
Publicado: (2019)

The effect of triptorelin and leuprolide on the level of sex hormones in girls with central precocious puberty and its clinical efficacy analysis
por: Wang, Lan, et al.
Publicado: (2021)

Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center
por: Chung, Lindsey Yoojin, et al.
Publicado: (2021)

Gonadotropin-releasing hormone analog therapies for children with central precocious puberty in the United States
por: Popovic, Jadranka, et al.
Publicado: (2022)

Short-term efficacy of 1-month and 3-month gonadotropin-releasing hormone agonist depots in girls with central precocious puberty
por: Jeon, Min Jin, et al.
Publicado: (2021)

Evaluation of Hypersensitivity Reactions with Leuprolide Acetate and Triptorelin Acetate in Children
por: Metbulut, Azize Pınar, et al.
Publicado: (2021)

A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients
por: Tunn, Ulf W
Publicado: (2011)

Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen
por: Lee, Young-jin, et al.
Publicado: (2020)

Precocious puberty in girls
por: Chittwar, Sachin, et al.
Publicado: (2012)

Precocious puberty in children
por: Atta, Irum, et al.
Publicado: (2013)

Management of precocious puberty
por: Tanaka, Toshiaki
Publicado: (2013)

Hepatoblastoma with Precocious Puberty
por: Yhoshu, Enono, et al.
Publicado: (2019)

Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation
por: Wex, Jaro, et al.
Publicado: (2013)

Pelvic Ultrasound Parameters of Long-Acting Depot Formulation of Leuprorelin in the Treatment of Idiopathic Central Precocious Puberty in Girls
por: Yang, Kun, et al.
Publicado: (2021)

Efficacy of Leuprorelin 3-Month Depot (11.25 mg) Compared to 1-Month Depot (3.75 mg) for Central Precocious Puberty in Chinese Girls: A Prospective Cohort Study
por: Yang, Jianmei, et al.
Publicado: (2022)

Transient central precocious puberty: a new entity among the spectrum of precocious puberty?
por: Assirelli, Valentina, et al.
Publicado: (2021)

Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer
por: Wu, Zhen-Yu, et al.
Publicado: (2021)

Contemporary issues in precocious puberty
por: Bajpai, Anurag, et al.
Publicado: (2011)

The characteristics of familial precocious puberty
por: Jeong, Hwal Rim, et al.
Publicado: (2015)

Treatment of Central Precocious Puberty
por: Eugster, Erica A
Publicado: (2019)

Genetic factors in precocious puberty
por: Shim, Young Suk, et al.
Publicado: (2021)

Therapeutic Effects of Leuprorelin (Leuprolide Acetate) in Sexual Offenders with Paraphilia
por: Choi, Jong Hyuk, et al.
Publicado: (2018)

Precocious puberty: A blessing in disguise!
por: Goswami, Soumik, et al.
Publicado: (2013)

Genetic causes of central precocious puberty
por: Tajima, Toshihiro
Publicado: (2022)

Childhood obesity and central precocious puberty
por: Shi, Li, et al.
Publicado: (2022)

Precocious puberty in patients with Pompe disease
por: Tsai, Meng-Ju Melody, et al.
Publicado: (2023)

Psychosocial Aspects in Girls with Idiopathic Precocious Puberty
por: Kim, Eun Young, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_4jgorbfg1hr5foekd04gnr5k9e